公开(公告)号：US10981962B2

公开(公告)日：2021-04-20

申请号：US16544738

申请日：2019-08-19

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  C07K19/00 ,  C07K14/47 ,  A61K38/01 ,  A61K38/17 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US10975425B2

公开(公告)日：2021-04-13

申请号：US15688765

申请日：2017-08-28

Applicant: UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASA

Inventor： Travis David Boone ,  Jimmy Kar Chuen Jung ,  Macarena Parra ,  Mark Brown

IPC: C12Q1/68 ,  C12N15/10 ,  C12Q1/686 ,  B01D61/18 ,  C12N15/09 ,  C12P19/34 ,  G01N33/53 ,  G05D7/06 ,  C12Q1/6806

Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.

公开(公告)号：US10975135B2

公开(公告)日：2021-04-13

申请号：US16787260

申请日：2020-02-11

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC: C07K16/26 ,  A61K39/395 ,  C12N15/09 ,  C12N15/63 ,  C07K14/705 ,  C07K16/28 ,  A61K38/17 ,  A61K38/22 ,  C07K14/47 ,  C07K14/72 ,  C07K16/18 ,  C12N5/07 ,  C07K16/42 ,  G01N33/68 ,  C07K14/575 ,  A61P25/06 ,  A61K38/00 ,  A61K48/00 ,  A61K39/00

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US10969390B2

公开(公告)日：2021-04-06

申请号：US15513707

申请日：2015-09-24

Applicant: NATIONAL CANCER CENTER ,  KYOTO UNIVERSITY ,  OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Hiroki Sasaki ,  Kazuhiko Aoyagi ,  Manabu Muto ,  Hiroo Takahashi

IPC: C12Q1/68 ,  G01N33/574 ,  C12N15/79 ,  C12Q1/6806 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886 ,  C12N15/09

Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).

公开(公告)号：US10947504B2

公开(公告)日：2021-03-16

申请号：US15735685

申请日：2016-06-16

Applicant: Kyoto University ,  Megakaryon Corporation

Inventor： Koji Eto ,  Sou Nakamura ,  Yukitaka Ito ,  Tomohiro Shigemori ,  Takeaki Dohda

IPC: C12N5/078 ,  A61K31/553 ,  A61K35/19 ,  A61K31/551 ,  C12N5/077 ,  C12N15/113 ,  C12N15/09

Abstract: The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.

公开(公告)号：US10920229B2

公开(公告)日：2021-02-16

申请号：US15523829

申请日：2015-05-18

Applicant: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

Inventor： Yong Wang ,  Zhiqiang Xiong ,  Shujie Song ,  Qiaoxia Liu ,  Jianfeng Wang

IPC: C12N15/70 ,  C12N15/113 ,  C12N9/12 ,  C12P19/62 ,  C12P17/08 ,  C07H17/08 ,  C12N15/09 ,  C12Q1/18 ,  C12R1/465

Abstract: The present invention relates to a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof. The yield of the polyketide heterologously synthesized by E. coli is significantly increased by attenuating the expression of seventy-two genes, such as sucC and talB, in a host strain, wherein the highest yield increase rate can reach 60% or more. Currently, erythromycin is the most clear model compound in the study on the biosynthesis of polyketids. The production strain of the present invention enables massive accumulation of 6-deoxyerythronolide (6-dEB), an erythromycin precursor, in the fermentation process, laying the foundation for the industrial production of the heterologous synthesis of erythromycin by E. coli.

公开(公告)号：US10919928B2

公开(公告)日：2021-02-16

申请号：US16009533

申请日：2018-06-15

Applicant: AJINOMOTO CO., INC.

Inventor： Kunihiro Hirai ,  Satoshi Katayama ,  Naoko Hirose ,  Taisuke Ichimaru ,  Ken Yamashita ,  Daisuke Takahashi

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/09 ,  C07H19/167 ,  C07H19/20 ,  C07H1/00 ,  C07H19/10 ,  C07H21/00 ,  C07H19/073 ,  C07H19/173 ,  C07H19/067

Abstract: Oligonucleotides may be produced by a process, including (1) condensing a nucleoside, nucleotide or oligonucleotide (b), and a nucleoside, nucleotide or oligonucleotide (a), or a substituted nucleotide or oligonucleotide (α) in a non-polar solvent to give a reaction solution containing a phosphite triester product (c); (3) oxidizing or sulfurizing the phosphite triester product (c) to give a reaction solution containing an oligonucleotide (d) wherein the 5′-hydroxy group is protected; (4) deprotecting the oligonucleotide (d) to give a reaction solution containing an oligonucleotide (e) wherein the 5′-hydroxy group is not protected; and (6) adding a polar solvent to the reaction solution containing the oligonucleotide (e) and purifying the oligonucleotide (e) by solid-liquid separation, wherein said nucleoside, nucleotide or oligonucleotide (a) or said substituted nucleotide or oligonucleotide (α) is a compound represented by formula (a-i): wherein Base, Rp1, R10, m, L, Y, and Z are defined herein.

公开(公告)号：US20210032282A1

公开(公告)日：2021-02-04

申请号：US16995477

申请日：2020-08-17

Applicant: National Institute of Advanced Industrial Science and Technology

Inventor： Yasuo KOMATSU ,  Yu HIRANO ,  Yasuhiro MIE

IPC: C07H21/04 ,  C12N15/113 ,  C12Q1/68 ,  C12N15/00 ,  A61K31/7088 ,  C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  C07H21/02 ,  C12Q1/6832

Abstract: A nucleic acid complex includes a single-stranded nucleic acid and a cross-linked double-stranded nucleic acid including the first nucleic acid strand linked to at least one of the 5′ end and the 3′ end of the single-stranded nucleic acid and the second nucleic acid strand including a base sequence that is completely or sufficiently complementary to the first nucleic acid strand.

公开(公告)号：US10906972B2

公开(公告)日：2021-02-02

申请号：US15549923

申请日：2016-02-12

Applicant: Tohoku University ,  ZENOAQ RESOURCE CO., LTD.

Inventor： Yukinari Kato ,  Mika Kaneko ,  Satoshi Ogasawara

IPC: C07K16/28 ,  C12N5/10 ,  G01N33/574 ,  C12N15/09 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00 ,  C12N15/02

Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.

公开(公告)号：US10906955B2

公开(公告)日：2021-02-02

申请号：US15995286

申请日：2018-06-01

Applicant: Pfizer Inc. ,  Boston Medical Center Corporation

Inventor： Stephen Berasi ,  Janet Elizabeth Buhlmann ,  Nathan Higginson-Scott ,  Michael Shamashkin ,  Matthew Russo ,  Stefano V. Gulla ,  Zong Sean Juo ,  Sreekumar R. Kodangattil ,  Weining Lu ,  Xueping Fan ,  David J. Salant

IPC: C07K14/705 ,  C07K19/00 ,  C12N15/09 ,  C12N15/11 ,  C12N15/52 ,  C12N15/63 ,  C07H21/04 ,  A61P13/12 ,  A61K38/17 ,  A61K38/00

Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.